Skip to content Skip to sidebar Skip to footer
Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed under the brand name Longidaza, is a polymer-conjugated hyaluronidase with an extended half-life. The study drug and placebo were administered for 71 days,…

Read more

How added sugars and sweetened foods impact the risk of 7 cardiovascular diseases

How added sugars and sweetened foods impact the risk of 7 cardiovascular diseases

Researchers uncover varying links between added sugar sources—like sweetened drinks, treats, and toppings—and risks for conditions such as heart failure, stroke, and aneurysms. Study:  Added sugar intake and its associations with incidence of seven different cardiovascular diseases in 69,705 Swedish men and women. Image Credit: Sorapop Udomsri / Shutterstock.com…

Read more

Higher cardiorespiratory fitness improves cognitive function in older age

Higher cardiorespiratory fitness improves cognitive function in older age

Higher cardiorespiratory fitness in older age is linked to the preservation of several core aspects of cognitive ability that are vulnerable to age-related decline, finds research published online in the British Journal of Sports Medicine. And this association holds true irrespective of key risk factors for cognitive decline: age and carriage of the high risk APOE4…

Read more

New biomarker testing protocol could shorten antibiotic treatment for sepsis

New biomarker testing protocol could shorten antibiotic treatment for sepsis

A major UK patient trial of a new biomarker testing protocol for sepsis, led by University of Manchester researchers, has shown it is possible to safely stop antibiotic treatment earlier than current care. The duration reduction of around 10% could provide significant cost savings to health systems, limit unwanted drug side-effects, reduce overtreatment and reduce…

Read more

£1M funding boost for new project to trial Parkinson’s treatments on digital twin brain

£1M funding boost for new project to trial Parkinson’s treatments on digital twin brain

£1m research project to advance ‘deep brain stimulation’ set to revolutionize Parkinson’s treatment and management. People with Parkinson’s disease are to benefit from cutting edge AI technology that allows neuroscientists to safely test medication and treatment on a ‘digital twin’ brain, thanks to a £1m funding boost for researchers at Manchester Met. The game-changing project…

Read more

the Kick-ass Multipurpose WordPress Theme

© 2025 Kicker. All Rights Reserved.